Literature DB >> 8102914

Exacerbation of ulcerative colitis during alpha-interferon therapy for chronic hepatitis C.

A Mitoro1, M Yoshikawa, K Yamamoto, M Mimura, Y Yoshikawa, A Shiroi, T Mochi, T Sakamoto, J Yamao, E Kikuchi.   

Abstract

We report a 34-year-old man with chronic hepatitis C who showed exacerbation of ulcerative colitis during alpha-interferon (IFN alpha) therapy. Discontinuance of the IFN alpha therapy improved his symptoms, suggesting that IFN alpha administration might worsen ulcerative colitis. The administration of sulfasalazine allowed the patient to receive IFN alpha again without flare-up of ulcerative colitis. This case suggests the possible efficacy of sulfasalazine therapy in patients with ulcerative colitis complicated by some other diseases requiring IFN alpha administration.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8102914     DOI： 10.2169/internalmedicine.32.327

Source DB:  PubMed          Journal:  Intern Med        ISSN： 0918-2918            Impact factor:   1.271


  12 in total

Review 1.  Autoimmune hepatitis and its variant syndromes.

Authors:  Z Ben-Ari; A J Czaja
Journal:  Gut       Date:  2001-10       Impact factor: 23.059

2.  A case of exacerbation of ulcerative colitis induced by combination therapy with PEG-interferon alpha-2b and ribavirin.

Authors:  T Watanabe; M Inoue; K Harada; N Homma; M Uchida; N Ogata; R Funada; K Hasegawa; K Soga; K Shibasaki
Journal:  Gut       Date:  2006-11       Impact factor: 23.059

Review 3.  Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver.

Authors:  María Rojas-Feria; Manuel Castro; Emilio Suárez; Javier Ampuero; Manuel Romero-Gómez
Journal:  World J Gastroenterol       Date:  2013-11-14       Impact factor: 5.742

4.  Interferon-α increases monocyte migration via platelet-monocyte interaction in murine intestinal microvessels.

Authors:  M Higashiyama; R Hokari; C Kurihara; T Ueda; M Nakamura; S Komoto; Y Okada; C Watanabe; A Kawaguchi; S Nagao; S Miura
Journal:  Clin Exp Immunol       Date:  2010-08-19       Impact factor: 4.330

5.  Imbalance of the interleukin 1 system in colonic mucosa--association with intestinal inflammation and interleukin 1 receptor antagonist [corrected] genotype 2.

Authors:  T Andus; R Daig; D Vogl; E Aschenbrenner; G Lock; S Hollerbach; M Köllinger; J Schölmerich; V Gross
Journal:  Gut       Date:  1997-11       Impact factor: 23.059

Review 6.  Immunomodulatory functions of type I interferons.

Authors:  José M González-Navajas; Jongdae Lee; Michael David; Eyal Raz
Journal:  Nat Rev Immunol       Date:  2012-01-06       Impact factor: 53.106

7.  Ischemic colitis during interferon-alpha treatment for chronic active hepatitis C.

Authors:  H Tada; S Saitoh; Y Nakagawa; H Hirana; M Morimoto; T Shima; K Shimamoto; T Okanoue; K Kashima
Journal:  J Gastroenterol       Date:  1996-08       Impact factor: 7.527

8.  Efficacy and safety of treatment of hepatitis C in patients with inflammatory bowel disease.

Authors:  Alina M Allen; W Ray Kim; Joseph Larson; Edward V Loftus
Journal:  Clin Gastroenterol Hepatol       Date:  2013-07-23       Impact factor: 11.382

Review 9.  Hepatitis C virus and inflammatory bowel disease.

Authors:  Todd L Horn; Joel Reynolds; Willem de Villiers; Luis R Peña
Journal:  Dig Dis Sci       Date:  2008-10-31       Impact factor: 3.199

10.  Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study.

Authors:  Claudia Pena Rossi; Stephen B Hanauer; Ratko Tomasevic; John O Hunter; Ira Shafran; Hans Graffner
Journal:  BMC Gastroenterol       Date:  2009-03-20       Impact factor: 3.067
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.